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Background: Although integrated treatments were implemented, glioblastoma 
multiforme (GBM) remains one of the most lethal primary brain tumors. The cellular 
retinoic acid–binding protein 2 (CRABP2) plays a crucial role, as one of the key 
cytoplasmic transport-proteins in retinoic acid (RA) pathway in various cancers, 
hence in GBM. Downregulation of CRABP2 protein and its lower ratio to fatty acid–
binding protein 5 (FABP5) were showed to play important role in impaired RA 
pathway and in survival time of GBM patients. The specific mechanism of CRABP2 
regulation in GBM is still not clear. Methods: Luciferase Reporter Assay was used to 
test hsa-mir-34a and hsa-mir-1262 mediated effects on 3’- untranslated region 
(3’UTR) of CRABP2 mRNA. In order to detect possible mutation in SUMOylation site, 
coding sequence of CRABP2 from different GBM tissues and cell lines was amplified 
and sequenced. Valproic acid (VPA) as histone deacetylation inhibitor, 5-aza-2'-
deoxycytidine (5-aza) as DNA methylation Inhibitor and RA were used to treat 
U87MG and patient-derived 36st GBM cell lines. Real-time PCR was used for mRNA 
quantification of CRABP2, FABP5, methyltransferase 1 (DNMT1), Caspase 7 and 
Bcl-2 DNA in cells treated with VPA, VPA+RA, 5-aza as well as in cells transfected 
with pcDNA4-CRABP2 plasmid. MTT assays were performed to detect GBM cells 
viability after VPA single and 5-aza single and in combination with RA treatment. 
Immunocytochemistry (ICC) was performed to detect expression of CRABP2 using 
anti-CRABP2, and proliferation level using anti-Ki-67 antibody. Results: 
Downregulation of CRABP2 in GBM is not due to its modulation by hsa-mir-34a and 
hsa-mir-1262 or a mutation in Lysine 102. VPA treatment alone and in combination 
with RA increased CRABP2 expression and inhibited proliferation and cell viability in 
GBM cells. Moreover, VPA treatment as well as 5-aza decreased DNMT 1 level in 
vitro. Besides that, both over-expression of CRABP2 as well as VPA treatment, 
increased apoptosis in glioblastoma cells. Conclusions: VPA increases expression 
of CRABP2 in analyzed GBM cell lines. Additional increase of CRABP2 expression 
was achieved by combined VPA and RA treatment. VPA+RA drug combination 
synergistically inhibited the proliferation of glioblastoma cells. This data suggests that 







1.1 Glioblastoma Multiforme (GBM) 
Within the central nervous system (CNS), human gliomas are recognized as the most 
common brain malignant neoplasia, which are classified as Grades I to IV according 
to the World Health Organization (WHO). Among that, GBM (WHO Grade IV 
glioblastoma) accounts for more than half of all gliomas and is the most lethal primary 
brain tumor in adults (Louis et al. 2007, Adamson et al. 2009).  
 
Glioblastoma “multiforme” displays that the tumor not only has high heterogeneity in 
histopathology but also shows inhomogeneity in both intertumoral and intratumoral 
aspects. Although in GBM integrated treatments, including surgery, specific regional 
radiotherapy and temozolomide (TMZ) chemotherapy are performed, median survival 
is still 14.8 months and less than 5% of patients survive longer than 5 years after the 
diagnosis (Ohgaki and Kleihues 2005, Wen and Kesari 2008). However, Barbus et al. 
found that among GBM patients there were 3-5% that can survive three years or 
longer (long term survivors, LTS, overall survival ≥ 36 months) (Barbus et al. 2011).  
 
Consequently, over the past decades, thousands of studies worldwide aim to search 
for more specific anti-GBM therapy so called personalized therapy (Shirai and 
Chakravarti 2011). Distinct strategies were applied and involved in study of different 
oncogenic pathways as for example angiogenesis (Wang et al. 2016), tumor 
immunology (Garg et al. 2016), epigenetic events (Nagarajan and Costello 2009) and 
glioma stem cells (GSCs) (Codrici et al. 2016). Chemoresistance and lack of 
accurate and reproducible biomarkers to select patients for specific therapies remain 
all the time the major therapeutic problems in GBM patients. The regulation of pro- 
and anti-apoptotic pathways is a key factor in the onset and maintenance of 








1.2 Retinoic Acid (RA) 
Retinoids can induce differentiation and/or apoptosis from cancer cellular perspective 
and display anti-proliferative and anti-oxidative activity. For this reason retinoids 
possess huge potential as chemotherapeutics (Altucci and Gronemeyer 2001). In a 
series of enzymatic steps, vitamin A (retinol) is metabolized through the oxidizing 
action of retinaldehyde (RDH) to retinal, and by retinaldehyde dehydrogenase 
(RALDH) to RA. RA has three different isomers: all-trans, 9-cis, and 13-cis RA. All-
trans RA (ATRA, RA) activates retinoic acid receptors (RAR α/β/γ), while 9-cis-RA 
activates RARs as well as retinoid X receptors (RXR α/β/γ) (Chambon 1996; 
Mangelsdorf 1994). RARs heterodimerize mostly with RXRs, which function as a 
transcription factor. RA, as an anti-carcinogenic agent, is currently used in the 
treatment of promyelocytic leukemia (Degos and Wang 2001, Chomienne et al. 
1990), and is being tested as a therapy for several types of human cancers (Buntzel 
and Kuttner 1998, Niles 2002, Arrieta et al. 2011, Bryan et al. 2011). Even though 
some encouraging results have been obtained from a phase 2 pilot study of RA given 
to patients with progressive or recurrent malignant glioma (Yung et al. 1996), efficacy 
of retinoids in glioma patients in clinical trials has been limited (Kaba et al. 1997, 
Phuphanich et al. 1997). It has been demonstrated that RA resistance may stem from 
the deregulated retinoid signaling (Campos et al. 2015, Jing et al. 1997).  
 
1.3 Cellular Retinoic Acid–Binding Protein 2 (CRABP2) in the RA pathway 
CRABP2, as one of the key cytoplasmic transport-proteins, plays a crucial role in the 
RA pathway (Liu et al. 2016). As one of the vitamin A metabolic molecules, RA once 
bound to CRABP2, is transported from cytoplasm into the nucleus via the activation 
of a nuclear localization signal (Corlazzoli et al. 2009). CRABP2 has higher binding 
affinity towards intracellular RA and once RA binds to CRABP2, it is directly delivered 
to the RAR α and RXR α/β/γ (Campos et al. 2011). This complex then binds to 
specific responsive elements in the promoters of target gene (Retinoic Acid 
Responsive Elements, RARE), and subsequently induces the gene expression of its 
downstream target (Campos et al. 2011). RA-activated RARs are involved in the 






cell differentiation (Rochette-Egly and Chambon 2001), proliferation (Vreeland et al. 
2014a), cell cycle arrest (Donato and Noy 2005, Donato et al. 2007) and apoptosis 
(Donato and Noy 2005).  
 
Alternatively, FABP5 is an intracellular lipid-binding protein which competes with 
CRABP2 for the RA, but with a less binding affinity. FABP5 shuffles RA to another 
nuclear receptor Peroxisomal Proliferator Activated Receptor β/δ (PPARβ/δ), which 
activates the genes involved more in proliferation (Schug et al. 2007). Liu et al. 
(2011) showed that in the case of higher cytoplasmic FABP5 to CRABP2 ratio in 
breast cancer, RA was preferentially bound to FABP5, thus cell survival increases 
instead of building the complex with CRABP2 which would contribute to the decrease 
of tumor cell survival (Liu et al. 2011). The analysis of Barbus et al. (2011) of GBM 
patients displayed low FABP5 to CRABP2 ratio in LTS, whereas a high FABP5 to 
CRABP2 ratio was detected in short term survivors (STS, overall survival ≤ 6 months) 
(Barbus et al. 2011).  
 
Downregulation of CRABP2 in medulloblastoma is due to the aberrant methylation in 
the promoter region (Fu et al. 2012). Campos et al. (2012) revealed that CRABP2 
expression is WHO grade-dependent (Campos et al. 2012). They also showed that 
downregulation of both total and nuclear CRABP2 plays a critical role in poor patient 
survival. Recently Yang et al. (2016) also stated that CRABP2 is downregulated in 
human esophageal squamous cell carcinoma and is considered as a tumor 
suppressor (Yang et al. 2016).  
 
1.4 Possible causes of CRABP2 downregulation in GBM 
Nagarajan and Costello (2009) classified epigenetic regulation in GBM as: non-
coding RNAs, covalent modifications of DNA (such as DNA methylation) and 
posttranslational modifications of N-terminal tails of histones (such as histone 
modifications) (Nagarajan and Costello 2009). Here the different types of epigenetic 
dysregulation are considered as potential reasons which could lead to 






MiRNAs as non-coding RNAs are a class of 21–25 nucleotide-long small RNAs (He 
and Hannon 2004). Chen et al. (2014) showed that RA induced expression of 
miRNA-302b which inhibits E2F3, a transcription factor leading to cell apoptosis in 
glioma (Chen et al. 2014). Furthermore, in neuroblastoma cells, Foley et al. (2011) 
also revealed that RA treatment induced expression of mir-10a/b which targets the 
nuclear receptor co-repressor 2 (NCOR2) (Foley et al. 2011). Downregulation of 
NCOR2 leads to the indirect suppression of MYCN, a potent onco-protein in 
neuroblastoma. This research demonstrated that RA induces the expression of 
miRNAs which are responsible for several tumor suppressive activities in the central 
nervous system. However, since the Campos group has indicated low CRABP2 
expression in GBM (Campos et al. 2011), the role of miRNAs in CRABP2 regulation 
is still unknown. Thus, it is possible that dysregulation of miRNAs in GBM could play 
a role in the downregulation of CRABP2.  
 
DNA methylation by DNA methyltransferases (DNMTs) has been reported to be a 
crucial type of covalent modifications of DNA. Among DNMTs, DNMT1 is a key 
enzyme which can maintain DNA methylation, especially through correcting 
methylation patterns on the new DNA strand during replication (Scott et al. 2014). 
Rajendran et al. (2011) have uncovered significant overexpression of DNMT1 in 
GBM (Rajendran et al. 2011). This emphasized the transcriptional silencing by CpG 
island methylation as a probable potential explanation for inactivation of several 
genes. Campos et al. (2012) revealed that DNA methyltransferase inhibitor 5-aza-2′-
deoxycytidine (5-aza) can reverse aberrant CpG methylation upstream of the 
CRABP2 gene locus in astrocytic gliomas (Campos et al. 2012). Therefore, DNA 
methylation could be one of the reasons which lead to decrease of CRABP2 in GBM 
cells. 
 
Histone deacetylation is one of the posttranslational modifications in N-terminal tails  
of histones and is known to regulate the expression of a whole range of genes in 
GBM (Cornago et al. 2014). Valproic acid (VPA), as a classic antiepileptic agent, was 






HDACs), and it is already approved as treatment of several cancers (Terranova-
Barberio et al. 2016, Leitch et al. 2016, Chen et al. 2009). Hosein et al. (2015) 
demonstrated that VPA as a therapeutic mono and in combination with TMZ and 
irradiation has distinct effect in primary GBM cells (Hosein et al. 2015). Moreover, as 
epigenetic therapy, DNMT inhibitor 5-aza with another HDAC inhibitor TSA can lead 
to the increase of more than 160 genes in GBM (Kim et al. 2006). However, it is still 
unknown whether histone deacetylation is one of the epigenetic causes resulting in 
CRABP2 downregulation. Thus, this study may answer the question if aberrant 
histone deacetylation is a potential reason causing the alteration in RA pathway 
particularly in downregulation of CRABP2.  
 
SUMOylation (Muller et al. 2001) is posttranslational modification where lysine 
residues are covalently attached to the target protein. Majumdar et al. (2011) showed 
that Lysine 102 (K102) residue of CRABP2 is amino acid SUMOylated in response to 
RA (Majumdar et al. 2011). SUMOylation of CRABP2 enhances its translocation to 
the nucleus in response to RA. Therefore, conceivably the mutations in K102 would 
enable CRABP2 protein to lose the ability to be SUMOylated leading to its 
dysfunction.  
 
1.5 Aims of the study 
Chemoresistance remains one of the major therapeutic problems in GBM. Retinoid 
can induce differentiation and/or apoptosis in tumor cells and therefore has great 
potential as chemotherapeutic. Sometimes the use of retinoid is hindered by 
deregulated RA signaling, for example deregulated CRAPB2 protein is related to 
GBM patient’s poor survival. I aimed at first to explore the potential transcriptional, 
posttranscriptional and posttranslational reasons for downregulation of CRABP2 
protein. Further on, this study was aimed to investigate the anti-cancer mechanism of 
a combined application of HDACi VPA and RA on glioblastoma by evaluating their 
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2 MATERIALS AND METHODS 
 
2.1 Materials and Chemicals 
Table 1.  Materials and chemicals and their sources used in the present study.  
 




Synergy MX multi-mode microplate reader
Clontech Labrotories /CA, USA Total Human Brain RNA
Fetal Bovine Serum (FBS)
Minimum Essential Medium (MEM)
0.05% Typsin-EDTA 
MEM Non-Essential Amino Acids (NEAA)
Sodium Bicarbonate Solution 7.5%
Sodium Pyruvate 100mM
Phosphate-Buffered Saline (PBS) pH7.4
Opti-MEM medium 
GraphPad Software /La Jolla, USA GraphPad Prism 5
Cell Culture Flask
6 , 12, 24, 96 well Culture Plate
pMIR-REPORT vector 
Lipofectamine 3000 
SuperScript III first-strand synthesis kit
New England Biolab Inc. /Ipswich, USA Spe l restriction enzyme
Greiner Bio-One /Frickenhausen, Germany
Invitrogen /Carlsbad, CA, USA
Bio-Rad /Hercules, USA
Bio-TEK /Winooski, USA
Gibco Life Technologies /Carlsbad, CA, USA
 






2.2 Cell Lines 
Glioblastoma cell lines: U87MG cells were a kind gift from Julia Bode (Molecular 
Mechanisms of Tumor Invasion, Schaller Research Group at the University of 
Heidelberg and the DKFZ), and 11st, 36st, 76st, 86st, 98st, 101st, 117st cell lines 
were derived from patient glioblastoma samples which were developed by Christoph 
Schmitz-Salue from the Neurosurgery department of the Georg-August University,  
 
 




Göttingen, Germany. This study was approved by the ethical board of University 
Clinic Göttingen. 
 
2.3 Luciferase Reporter Assay 
For this assay the cells were seeded in 96-well plates at a cell density of 5x104 
Human Embryonic Kidney 293 (HEK293) cells per well and incubated at 37°C. One 
day later the medium was changed into Opti-MEM medium without FBS and the cells 
were transfected with relevant plasmids (pMIR-REPORT firefly luciferase vector or 
pMIR-REPORT-CRABP2-3’UTR vector together with pGL4.73 Renilla luciferase 
vector) as well as with hsa-mir-1262 and with hsa-mir-34a respectively in three 
replicates per condition (Table 2). 6-8 hours later 50 µl per well medium with FBS 
was added. 24 hours after the transfection the cells were washed and lysed for 
luciferase assay according to the manufacture protocol. 20 μl of cell lysate per well 
was mixed with 100 μl of Luciferase Assay Reagent and immediately measured 
using luminometer from BioTek Synergy MX Monochromator-based multi-mode 
microplate reader.  
 
Table 2. Cell transfection used in Luciferase Reporter Assay. 
 
 












pGL4.73  (150ng) pGL4.73  (150ng) pGL4.73  (150ng)
hsa-mir-34a or  
hsa-mir-1262    
(10 pg) 
hsa-mir-34a or  
hsa-mir-1262    
(10 pg) 
mir-negative      
control  (10 pg) 

 




2.4 Construction of pcDNA4-CRABP2 plasmid and its transfection in U87MG 
Template cDNA was generated using mRNA from Total Human Brain (RNA was from 
#636530, Clontech Labrotories, CA, USA) and Superscript III reverse trancriptase. 
The CRABP2 coding sequence was amplified by PCR using the template cDNA. The 
following primers were used: forward 5’-CGG AAT TCC GAT GCC CAA CTT CTC 
TGG C -3’ and reverse 5’-GGG GTA CCC CCT CTC GGA CGT AGA CCC T -3’. The 
PCR product was purified on 1% TAE agarose gel, digested with EcoRI and KpnI 
restriction enzymes and cloned into the pcDNA4/myc-HisB mammalian expression 
vector. The correct sequence as well as the reading frame of CRABP2 was 
confirmed by sequencing. U87MG cells were transfected with plasmid pcDNA4-
CRABP2 or pcDNA4/myc-HisB using Lipofectamine 3000. Solution I was prepared by 
diluting 1.5 µl Lipofectamine 3000 reagent in 25 µl Opti-MEM medium.  For the 
solution II, 1 µg of DNA was diluted in 25 µl Opti-MEM medium and mixed with 2 µl of 
P3000 reagent.  These two solutions were mixed, incubated for 5 minutes at room 
temperature and applied on the cells. After 6-8 hours, 100 µl per well medium 
(containing FBS) was added. RT-PCR and ICC analysis were performed 24 hours 
after the transfection.  
 
2.5 Real-time Quantitative PCR 
Cellular RNA was isolated with the RNeasy kit. RNA (1 µg) was reverse-transcribed 
into cDNA by using SuperScript III first-strand synthesis kit. cDNA (100 ng) was used 
for real-time PCR amplification. Real-time PCR was performed on a BioRAD CFX384 
cycler using SYBR-Green Mastermix and gene-specific primers of following genes: 
CRABP2, FABP5, DNA methyltransferase 1 (DNMT1), Caspase 7 and Bcl-2 (Table 
3). The amplification was carried out by using the following cycle protocol; 95°C for 
15 s; 60°C for 30 s, repeating it for 40X. Data were normalized to 













2.6 Cell Viability Assay 
Cell viability assay was performed by using 3-(4, 5-dimethylthiazol)-2, 5-
diphenyltetrazolium bromide (MTT). Briefly, cells were seeded in medium with FBS in 
96-well plates at a cell density of 104 cells per well and incubated at 37°C. After 24 
hours cells were washed with 1X phosphate-buffered saline (1X PBS), medium 
without FBS was added and the cells were treated with appropriate treatments. After 
incubation period of 72 hours, 10 µl of MTT solution was added and the cells were 
incubated for a further 4 hours at 37°C. Samples were measured with a 
spectrophotometer absorption reader using absorbance at 562 nm. 
 
2.7 Cell Proliferation Assay 
Glioblastoma cells were seeded in two replicates on 24-well poly-D-lysine-coated 
plates with 1x105 cells per well. The cells were treated as described in Figure 1, fixed 
with methanol for 20 minutes at -20°C, and washed three times by 1X PBS. 
Afterwards, coverslips were incubated 20 minutes in 1X PBS containing 0.2% Triton 
X100 and 10% normal horse serum, following washing three times with PBS/1% 
horse serum. Then coverslips were incubated with primary antibody (anti-mouse-Ki-
67, 1:100, Clone MIB-1, DAKO, Glostrup, Denmark) in 1X PBS, 1% horse serum, 
 




0.2% Triton X100 overnight at 4°C. Next, coverslips were washed three times with 1X 
PBS and incubated in the dark with Alexa Fluor 488 donkey anti-mouse IgG 
secondary antibody (1:500, Life Technologies, Carlsbad, USA) in 1X PBS with 1% 
serum and 0.2% Triton X100 for one hour at room temperature. After washing three 
times with 1X PBS, coverslips were counterstained with DAPI. At last the coverslips 
were dried at room temperature and mounted with Aqua Polymounting medium. The 
slides were examined with ZEISS Axiovert 200 Fluorescence Microscopy. The 
proportion of Ki-67 positive cells was counted using 20X microscopic amplification. 
Each treatment was performed with at least three independent experiments and each 
experiment was analyzed based on at least five random microscopic fields. 
 
2.8 Immunocytochemistry (ICC) 
Glioblastoma cells were seeded in two replicates on 24-well Poly-D-lysine-coated 
plates with 1x105 cells per well. The cells were treated and fixed as described above. 
For the staining a primary anti-goat-CRABP2 (1:50, sc-10065, Santa Cruz 
Biotechnology, Dallas, USA) antibody and secondary antibody Alexa Fluor 546 
donkey anti-goat IgG (1:500, Life Technologies, Carlsbad, USA) were used following 
the above described protocol. 
 
2.9 Experimental design of cell treatment   
One day before the treatment (-1) the glioblastoma cells were seeded in appropriate 
replicates already described for each performed test. On day 0 medium was 
aspirated, the cells were washed with 1X PBS and replaced with medium without 
FBS, in order to exclude undefined effect of the FBS medium. NC (negative control) 
group was treated with dimethylsulfoxide (DMSO); VPA group was treated with 
DMSO and VPA; V+R group was treated with VPA and RA; RA group was treated 
with RA. On day 1 and 2, NC and VPA groups were treated additionally with DMSO 
in order to mimic RA, which was diluted in DMSO; V+R and RA groups were treated 
with RA. On day 3, after the glioblastoma cells were treated with VPA and/or RA for 
72 hours, subsequent analyses were done according to the protocol for the real-time 
PCR, MTT assay and ICC. 
 




2.10 Statistical Analysis 
All in vitro data was performed in at least triplicate. The significance of differences 
was analyzed using two-sided t-tests for two-group comparisons. Calculations were 
performed using the statistics software GraphPad Prism 5. A probability of P < 0.05 
was considered as statistical significance. The combination index (Chou and Talalay 













3.1 3’UTR of CRABP2 mRNA is not the target of hsa-mir-34a and hsa-mir-1262 
in glioblastoma cells   
In recent decades non-coding RNAs such as miRNAs and long non-coding RNAs 
(lncRNAs) are more and more discussed in the fields of regulation of gliomas. As one 
of the key epigenetic gene regulation effectors, miRNAs contribute extensively to the 
downregulation of a wide range of target genes such as tumor suppressors and many 
epigenetic key enzymes in cancers. I hypothesized that miRNA could be one of the 
reasons causing the downregulation of CRABP2. At first the possible miRNAs which 
could target CRABP2, as well as their hypothetic position within 3’UTR of CRABP2 
mRNA were searched through open-public microRNA database “miRwalk” 
(www.umm.uniheidelberg.de/apps/zmf/mirwalk/) and “miRBase” (www.mirbase.org/). 
The analysis revealed two miRNAs: hsa-mir-34a and hsa-mir-1262 could putatively 




Figure 1. The hypothetic target positions of hsa-mir-34a (A) or hsa-mir-1262 (B) on CRABP2 
mRNA 3’UTR according to microRNA database “miRwalk” and “miRBase”. 
 
Furthermore, in order to check the expression of these miRNAs in low grade gliomas 
compared to GBM I used “The Cancer Genome Atlas (TCGA) Data Portal” (by 
National Cancer Institute and National Human Genome Institute). I found that hsa-
mir-34a and hsa-mir-1262 are significantly higher expressed in glioblastomas (n=17) 
compared to the one in low grade gliomas (n=17) (p=0.0438, p=0.0057) (Figure 2 







Figure 2. Heat map presenting the expression profiles of hsa-mir-34a and hsa-mir-1262 





Figure 3. Real-time PCR analysis of data from TCGA showed that hsa-mir-34a (A, 
p=0.0438) and hsa-mir-1262 (B, p=0.0057) were increased significantly in 17 low grade 
gliomas compared to 17 GBM tissues. Bars depict mean ± S.E.M. from three independent 
experiments. Statistical analysis was performed using two-sided t-tests for two-group 
comparisons (*P<0.05, **P<0.01).  
 
In order to determine the effect of miRNAs on the activity of CRABP2-3’UTR 
luciferase assays were performed in HEK293 cells. Human brain total RNA was used 
to generate cDNA by reverse transcription. This cDNA was used as a template to 






Spel restriction enzymes and ligated into the pMIR-REPORT (Figure 4 A) firefly 
luciferase vector. pMIR-REPORT -CRABP2-3’UTR (Figure 4 B) vector was co-
transfected with pGL4.73 (Figure 4 C) renilla luciferase vector, as well as hsa-mir-
1262 and hsa-mir-34a respectively, in HEK293 cells. The luciferase activities of the 
cells co-transfected with pMIR-REPORT-CRABP2-3’UTR and hsa-mir-34a or hsa-
mir-1262 did not show any significant differences compared with control groups. This 
suggests that in these trials, hsa-mir-34a and hsa-mir-1262 do not target CRABP2 










        
 
Figure 4. The commercially available pMIR-REPORT (A) firefly luciferase vector and 
pGL4.73 (C) renilla luciferase vector and pMIR-REPORT-CRABP2-3’UTR firefly luciferase 
vector (B) which was constructed according to HindIII-SpeI restriction sites and CRABP2 
mRNA 3’UTR sequence. 
 
3.2 Downregulation of CRABP2 protein in glioblastomas is not due to the 
mutation in Lysine 102  
Majumdar et al. showed that E2SUMO ligase Ubc9 interacts with CRABP2 and 
hence SUMOylates the CRABP2 protein. Lysine 102 (K102), as one of three putative 
SUMOylation sites of CRABP2, is SUMOylated and is essential for the mobilization of 
CRABP2 protein into nucleus and its delivery of RA to RAR-RXR transcriptional 
activation.  
Protein and mRNA expression analysis from 10 GBM tissues, 7 cell lines derived 
from glioblastoma patients tissue; 11st, 36st, 76st, 86st, 98st, 101st, 117st and from 
U87MG commercially available cell line showed low CRABP2 expression (data not 
shown). In order to check if the eventual mutation in K102 is the reason for its 
downregulation, at first, we extracted mRNAs of these samples and generated cDNA 
using reverse transcriptase. These cDNAs were used to amplify CRABP2 product 
(showed in Materials and Methods) by PCR and to clone it in to pGEM-T Easy 
Vector. DNA from these samples was amplified and sequenced using pGEM-T Easy 
specific primers. I could not detect any mutation in sequence coding for K102 
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  pGL4.73 






residue, the amino acid responsible for SUMOylation of CRABP2 and mobilization of 
the CRABP2 protein into the nucleus.  
 
3.3 Effect of combined VPA and RA treatment on CRABP2 expression in GBM 
cells  
Histone deacetylation is known as one of the epigenetic modifications by which 
expression of many genes were regulated in GBM. Here we showed that treatment of 
U87MG and patient-derived 36st glioblastoma cells with VPA (10 mM) upregulates 
CRABP2 expression. Detailed experimental design of treatment according to time 




Figure 5. Schematic presentation of the experimental design. One day before the treatment 
(-1) the glioblastoma cells were seeded in appropriate replicates. On day 0, NC group was 
treated with DMSO; VPA group was treated with DMSO and VPA; V+R group was treated 
with VPA and RA; RA group was treated with RA. On day 1 and 2, NC and VPA groups were 
treated with DMSO; V+R and RA groups were treated with RA. On day 3, after 72 hours of 
treatment, subsequent analyses were done accordingly to the protocol for the Real-time 
PCR, MTT assay and ICC. MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; ICC:  Immunocytochemistry; VPA:  Valproic acid, with 2 mM, 5 mM, 10 mM 






Even though CRABP2 mRNA expression was increased after VPA, significant 
upregulation (p=0.0094, p=0.0408) was achieved using V+R treatment for three days 
in U87MG and 36st glioblastoma cells (Figure 6).  
 
 
Figure 6. Real-time PCR analysis showed that CRABP2 expression was increased 
significantly after combined VPA (10 mM) and RA (5 µM) treatment for three days, in U87MG 
(left, p=0.0094) and 36st (right, p=0.0408) GBM cells. Bars depict mean ± S.E.M. from three 
independent experiments. Statistical analysis was performed using two-sided t-tests for two-
group comparisons (*P<0.05, **P<0.01). 
 
Moreover, the ratios of FABP5/CRABP2 in these treatment groups were 
consequently downregulated, as showed by analysis of real-time PCR results, in 
which V+R (p=0.0160, p=0.0493) groups revealed notably reduction in U87MG and 













Figure 7. Real-time PCR analysis showed that the ratios of FABP5/CRABP2 were 
decreased in V+R group in U87MG (left, p=0.0160) and 36st cells (right, p=0.0493). Bars 
depict mean ± S.E.M. from three independent experiments. Statistical analysis was 
performed using two-sided t-tests for two-group comparisons (*P<0.05). 
 
Furthermore, ICC experiments not only supported that VPA and V+R treatment can 
increase CRABP2 protein expression in glioblastoma cells (Figure 8 A and C), but 
also revealed different cellular localization of this protein. Treatment of these GBM 
cells with VPA shows cytoplasmic localization of CRABP2 protein, where V+R groups 
show more nuclear localization (Figure 8 B and D). Given that CRABP2 is one of the 
key RA transport-proteins, CRABP2 with more nuclear localization in V+R groups 














Figure 8. VPA in combination with RA upregulate CRABP2 expression in GBM cells. ICC 
experiments showed that VPA, V+R treatment can increase CRABP2 protein expression in 






different cellular localization of CRABP2 proteins. Treatment of U87MG (B) and 36st (D) cells 
with VPA showed cytoplasmic localization of CRABP2 protein, where V+R group showed 
more nuclear localization. The scale bar is 50 µm. 
 
3.4 VPA treatment alone and in combination with RA inhibit proliferation and 
cell viability of GBM cells  
Next we tested the proliferation ability of GBM cells under VPA and RA treatments. It 
is already known that VPA can inhibit proliferation of GBM cells in vitro. Staining of 
both cell lines with anti-Ki-67 antibody (cellular proliferation marker) showed less Ki-
67 stained cells after treatment with 10 mM VPA. Yet again, the combination of both 
drugs showed a stronger inhibition of the proliferation compared with single treatment 














Figure 9. VPA treatment alone and in combination with RA inhibits proliferation and cell 
viability of GBM cells. A and B Cell proliferation assay showed less Ki-67 (cellular 
proliferation marker) stained cells after treatment with 10 mM VPA. Furthermore, combination 
V+R showed stronger inhibition of the proliferation compared with single treatment in both 
U87MG (A) and 36st (B) cell lines. The scale bar is 100 µm. 
 
Furthermore, it was found that combined treatment with VPA and RA synergistically 
decreases the proliferation, since the proportion of Ki-67 positive cells was 
considerably lower compared with NC (p=0.0009, p=0.0025) or VPA single treatment 















Figure 10. The proportion of Ki-67 positive cells in V+R groups were considerably lower 
compared with NC (p=0.0009, p=0.0025) or VPA single treatment group (p=0.0172, 
p=0.0327) in U87MG (left) and 36st (right) cell lines. Cell Proliferation Assays with anti-Ki-67 
antibody were performed at least in three independent experiments in both cell lines. Bars 
depict mean ± S.E.M. from three independent experiments. Statistical analysis was 
performed using two-sided t-tests for two-group comparisons (*P<0.05, **P<0.01, 
***P<0.001). 
 
Using MTT assay it was shown that the cell viability in U87MG (p=0.0115) and 36st 
(p=0.0432) was inhibited after 72 hours treatment with VPA (Figure 11).  Similarly in 
MTT assay, V+R group showed a very strong decrease in cell viability compared to 
both control (p<0.0001, p=0.0006) and VPA single (p=0.0115, p=0.0006) treatment 

















Figure 11. The cell viability in U87MG (left, p=0.0115) and 36st (right, p=0.0432) was 
inhibited after 72 hours treatment with VPA alone. Furthermore, V+R group showed 
significant higher decrease in cell viability comparing to both, control and VPA single 
treatment. Bars depict mean ± S.E.M. from three independent experiments. Statistical 
analysis was performed using two-sided t-tests for two-group comparisons (*P<0.05, 
**P<0.01, ***P<0.001). 
 
Besides this, the reduction of VPA concentration up to 2 mM in combination with RA 
was still able to show significant effect on U87MG and 36st cell lines (Figure 12 A 
and B) in MTT assays. More specifically, MTT assay showed that the cell viability in 
U87MG and 36st was inhibited with V2+R (p=0.0018, p=0.0277) and V5+R 
















Figure 12. The reduction of VPA concentration up to 2 mM in combination with RA was still 
able to cause significant reduction in cell viability in U87MG (left) and 36st (right) cell lines. 
VPA10: 10 mM; VPA5: 5 mM; VPA2: 2 mM. Bars depict mean ± S.E.M. from three 
independent experiments. Statistical analysis was performed using two-sided t-tests for two-
group comparisons (*P<0.05, **P<0.01, ***P<0.001). 
 
3.5 VPA treatment as well as DNA methylation Inhibitor 5-aza decrease DNMT1 
levels in GBM cells 
DNA methylation leads to downregulation of CRABP2 on transcriptional level. Since 







of this enzyme was examined. Firstly, DNA methylation inhibitor 5-aza was used in 
concentration of 2 µM or 10 µM for three days in order to confirm the influence of 
DNA methylation on CRABP2 in U87MG glioblastoma cells.  The results of real-time 
PCR showed that 10 µM of 5-aza significantly increased (p=0.0444) the expression 




Figure 13.  The real-time PCR showed that 10 µM DNA methylation inhibitor 5-aza 
significantly increased (p=0.0444) the expression of CRABP2 mRNA in U87MG cell lines. 
Data were normalized to hydroxymethylbilane synthase (HMBS) levels. Bars depict mean ± 
S.E.M. from three independent experiments. Statistical analysis was performed using two-
sided t-tests for two-group comparisons (*P<0.05). 
 
Besides this, decreased cell viability was detected by MTT assay under the treatment 
of the U87MG with 10 µM 5-aza alone (p=0.0422) and 10 µM 5-aza combined with 













Figure 14.  U87MG cell viability decreased notably in MTT assay by treatment with 10 µM 5-
aza (p=0.0422) and 10µM 5-aza combined with 5 µM RA (p=0.0434). Bars depict mean ± 
S.E.M. from three independent experiments. Statistical analysis was performed using two-
sided t-tests for two-group comparisons (*P<0.05). 
 
The real-time PCR results showed that treatment of GBM cells with VPA and V+R 
prominently downregulated the expression of DNMT1 in both U87MG (p=0.0359, 
p=0.0484) and patient-derived 36st (p=0.0002, p=0.0021) GBM cell lines (Figure 15). 
 
 
Figure 15. VPA treatment decreases DNMT1 levels in GBM cells. Bars depict mean ± S.E.M. 
from three independent experiments. Statistical analysis was performed using two-sided t-






3.6 Overexpression of CRABP2 as well as VPA treatment increase apoptosis in 
vitro 
In order to prove the specific effect of CRABP2 on GBM cells we transfected 
pcDNA4-CRABP2 plasmid (Figure 16 B) in U87MG cell lines. The coding sequence 
of CRABP2 has been cloned with the correct reading frame in the expression plasmid 
pcDNA4/myc-HisB (Figure 16 A) using EcoRI-KpnI restriction sites. Transfection of 
U87MG GBM cells with pcDNA4-CRABP2 plasmid increased cell death as detected 
by immunofluorescence staining with propidium iodide (PI), (Figure 17).   
 
               
 
               
 
Figure 16. The commercially available pcDNA4/myc-HisB plasmid (A), and constructed 
pcDNA4-CRABP2 plasmid (B) CRABP2 coding sequence was cloned using EcoRI-KpnI 








Figure 17. Overexpression of CRABP2 as well as VPA treatment increase apoptosis in vitro. 
Transfection of U87MG glioblastoma cells with pcDNA4-CRABP2 plasmid increased cell 
death as detected by staining with the fluorescent molecule, propidium iodide (PI). The scale 
bar is 50 µm. 
 
Real-time PCR also showed that U87MG and 36st cells over-expressing CRABP2 by 
transfection of pcDNA4-CRABP2 plasmid (Figure 18) distinctly induced more 
Caspase 7 in comparison to the control transfected with plasmid without CRABP2 
coding sequence (p=0.0333, p=0.0447; Figure 19). 
                  
 
Figure 18. CRABP2 expression level in U87MG (up) and 36st cells (down) after transfection 









Figure 19. Caspase 7 mRNA level in U87MG (left) and 36st (right) cells with over-expressing 
CRABP2. Bars depict mean ± S.E.M. from three independent experiments. Statistical 
analysis was performed using two-sided t-tests for two-group comparisons (*P<0.05). 
 
Furthermore, GBM cells over-expressing CRABP2 showed Caspase 7 mRNA 
increase which correlates with the increased Caspase 7 after V+R treatment 
(p=0.0457) (Figure 20). Interestingly, although of similar tendency, significant 
increase in Caspase 7 has not been observed for the 36st cell line treated with VPA 
or V+R. It is possible that a different genetic background, for example influence of 















Figure 20. In correlation with GBM cells over-expressing CRABP2, VPA-treated groups 
showed increased Caspase 7 mRNA expression. Considerable increase was detected in 
U87MG cells after V+R treatment (left, p=0.0457). Bars depict mean ± S.E.M. from three 
independent experiments. Statistical analysis was performed using two-sided t-tests for two-
group comparisons (*P<0.05). 
 
Considering the fact that GBM are characterized by high expression level of anti-
apoptotic Bcl-2 protein (Krajewski et al. 1997, Kraus et al. 2001) we examined the 
influence of V+R on its mRNA expression level. Both tested cell lines displayed 
remarkably lower mRNA expression of anti-apoptotic member Bcl-2, especially in 














Figure 21. mRNA expression of anti-apoptotic marker Bcl-2 in U87MG (left) and 36st (right) 
cells. Lower expression of Bcl-2 was detected especially in V+R group (p=0.0139, p=0.0466). 
Bars depict mean ± S.E.M. from three independent experiments. Statistical analysis was 




















Alterations in RA signaling are very frequently observed in GBM (Campos et al. 
2011) and are used to explain RA resistance in some cases (Campos et al. 2015, 
Zhou et al. 2015). Recently, Yang et al. (2016) showed downregulation of CRABP2 in 
human esophageal squamous cell carcinoma and its role as a tumor suppressor 
(Yang et al. 2016). Among CNS proteins CRABP2 plays a crucial role in RA pathway 
and is downregulated in medulloblastoma and GBM. The downregulation is at least 
partially due to the aberrant methylation in its promoter (Fu et al. 2012, Campos et al. 
2012).  
 
4.1 Decrease of CRABP2 in GBM is not modulated by hsa-mir-34a and hsa-mir-
1262 and mutation in K102  
It is already known that upregulation or downregulation of miRNAs alter the 
expression of a lot of proteins in GBM (Tao et al. 2013, Que et al. 2015, Hu et al. 
2016). My assumption that miRNAs: hsa-mir-34a and hsa-mir-1262 can target 
CRABP2 mRNA 3’UTR and potentially be responsible for downregulation of CRABP2 
in GBM could not be confirmed. In fact, according to miRNA database, besides hsa-
mir-34a and hsa-mir-1262, there are still numerous predicted potential miRNAs which 
are supposed to target CRABP2 but which are not tested in this study. Furthermore, 
hsa-mir-34a and hsa-mir-1262 have also other target genes which may have indirect 
effect on RA pathway in GBM. Based on these views, I still could not exclude 
miRNAs as one of the reasons leading to downregulation of CRABP2.  
 
Majumdar et al. (2011) demonstrated that K102 in CRABP2 is the residue which is 
SUMOylated, and SUMOylation of CRABP2 could enhance its translocation to the 
nucleus in response to RA (Majumdar et al. 2011). Since in GBM CRABP2 is mostly 
located in cytoplasm I assumed the mutation in this amino acid could be responsible 
for CRABP2 cytoplasmic localization (Liu et al. 2016). However, I could not detect 





the aberrant SUMOylation in GBM could not be completely excluded since this study 
the aberrant SUMOylation in GBM could not be completely excluded since this study 
did not directly address the Ubc 9 or other key SUMOylational enzymes analysis 
(Hsieh et al. 2013). 
 
4.2 CRABP2 expression increases after VPA treatment in GBM cells 
Data presented in this work shows that the HDAC inhibitor VPA increases expression 
of CRABP2 in two GBM cell lines. That increase could be due to the known function 
of VPA as an HDAC inhibitor, leading to decondensation of the chromatin which in 
turn derives to subsequent higher expression of CRABP2. Alternatively this effect 
could be the consequence of the VPA effect on downregulation of DNMT1 (Sarkar et 
al. 2011) enzyme activity on the promotor region of CRABP2 gene (Figure 15). 
DNMT1 adds methyl groups on the fifth carbon of cytosine at CpG sites and therefore 
results in DNA methylation that finally leads to suppression of gene transcription. 
Hence, inhibition or inactivation of DNMT1 leads to DNA hypomethylation or 
demethylation, in this case possibly of the CRABP2 promotor region (Brodie et al. 
2014). On the other hand, VPA has been discovered to induce DNA hypomethylation 
in rat astrocytes and that is reversible and independent of DNMT1 (Perisic et al. 
2010). In this case these results would suggest that VPA affects chromatin 
remodeling properties of active demethylation machinery in the promoter regions of 
DNMT1 and CRABP2. Direct influence of DNMT1 on CRABP2 promotor methylation 
was not examined in this study. 
 
4.3 Nuclear re-localization of CRABP2 after VPA+RA in GBM cells  
ICC staining confirmed the expression of CRABP2 protein, as well as indicating its 
cytoplasmic localization after exposure to VPA. Further increase of CRABP2 protein 
expression, as well as more nuclear localization, was observed when VPA was 
added to the GBM cell lines in combination with RA (Figure 8 B and D). This is in 
agreement with the known, and main, function of CRABP2 protein, to transport RA to 
the nucleus (Connolly et al. 2013) and that transcription of CRABP2 is RA dependent 
(Astrom et al. 1994). Moreover VPA and RA application lowers the ratio of 






between long and short term GBM survivors (Barbus et al. 2011). LTS GBM patients 
have lower FABP5/CRABP2 ratio compared to STS which show higher 
FABP5/CRABP2 ratio (Barbus et al. 2011). 
 
4.4 VPA+RA treatment increased apoptosis and decreased proliferation in GBM 
cells 
VPA treatment increased apoptosis in both GBM cell lines. Yet again a stronger 
effect on the cell death of these cell lines was increased under combined treatment. It 
is already known that VPA induces apoptosis in GBM by influencing the balance 
between pro-apoptotic genes such as Bax, p53 and anti-apoptotic genes such as 
Chk1 and Bcl-2 (Cornago et al. 2014). Similar VPA effects on gene expression have 
also been described in cervical carcinoma (Feng et al. 2012). Treatment of GBM cell 
lines with VPA confirmed the known effect on downregulation of the anti-apoptotic 
gene Bcl-2. Combining V+R, increased the expression of Caspase 7, an apoptotic 
marker. This increase is at least partially due to the expression of CRABP2, because 
transfection of CRABP2 into these GBM cell lines led to a similar increase of 
Caspase 7 mRNA. This result is in agreement with another recently shown function 
of CRABP2, in stabilizing some mRNA through interaction with HuR (Vreeland et al. 
2014b). Vreeland et al. (2014a) have presented a mechanism which explains anti-
carcinogenetic activity of CRABP2 with or without RA in GBM (Vreeland et al. 
2014a). It includes involvement of CRABP2 in HuR-mediated mRNA stabilization, in 
addition to the RAR mediated transcriptional regulation.  
 
Based on above presented results, I speculate that, on one side CRABP2 directly 
interacts with HuR, markedly improving its RNA-binding affinity, and therefore 
boosting the stability of HuR-targeted transcripts, for example Caspase 7 mRNA 
(Figure 22). On the other hand, binding of CRABP2 to RA induces its dissociation 
from HuR. Once bound to RA it is transported to the nucleus, where it delivers RA to 







These would be in agreement with Vreeland et al. (2014b) who demonstrated the 
anti-carcinogenic activity of CRABP2 is by promoting HuR-mediated stabilization of 
transcripts of proteins that inhibit proliferation, and by raising RA-induced RAR-
mediated transcription of growth-inhibitory genes (Vreeland et al. 2014b). Results of 
this study have shown that VPA increases CRABP2 cytoplasmic expression which in 
turn induces apoptosis, e.g. through stabilization of Caspase 7 mRNA. The addition 
of RA causes translocation of CRABP2 to the nucleus which further induces 
apoptosis due to the activation of RAR genes.  
 
Additionally, it is important to mention that transcription of CRABP2 is RA-dependent 
so that RA not only activates RAR genes but is also responsible for its own 
transcription and own turnover (Astrom et al. 1994). Increased cell death and 
decreased proliferation by combined treatment is at least partially a consequence of 
these effects, since I cannot exclude the influence of VPA on overall gene expression 
and its changes in distinct biological pathways (Zhang et al. 2013).  
 
        
                                                                                                                                           






potential action of VPA+RA on CRABP2 expression in U87MG and 36st glioblastoma cell 
lines. VPA induces expression of CRABP2 in cytoplasm which can bind HuR protein and 
enhances the stability of Caspase 7 mRNA and induces apoptosis in these cells. Added RA 
binds to CRABP2 protein in cytoplasm and is delivered to the nucleus where it induces RAR-
mediated transcriptional regulation which leads to the inhibition of proliferation. Additionally, 
CRABP2 is RA-dependent so that RA not only activates RAR genes but is also responsible 
for its own transcription and own turnover. 
 
4.5 Potential of VPA+RA as anti-cancer therapy in GBM 
In human breast cancer cells Mongan and Gudas (2005) revealed that VPA, in 
combination with RA and the DNA methyltransferase inhibitor 5-aza, can overcome 
the epigenetic barriers to transcription of a prototypical silenced tumor suppressor 
gene, RARβ2 (Mongan and Gudas 2005). VPA is an approved classic drug for the 
treatment of epileptic seizures, bipolar disorders, and migraine (Mongan and Gudas 
2005). Recently VPA is being conducted in different countries in Phase 1 and 2 
clinical trials as an anti-cancer drug for the treatment of GBM, alone or in combination 
with TMZ or radiation (Clinicaltrials.gov ID: NCT00943826, NCT00689221, 
NCT00313664). RA with its anti-carcinogenic properties was tested for therapy in 
several types of human cancer including GBM (Yung et al. 1996). The data from cell 
viability assay with 2 mM and 5 mM VPA in combination with RA also suggests the 
possibility to reduce the dose of VPA in order to reduce the side effect of VPA. The 
combination of VPA with RA has not been conducted in anti-cancer therapy in GBM 
patients. Even though the results I presented here need more support with in vivo 
experiments, it could encourage evaluation of this drug combination in anti-glioma 












In this study, I examined various possibilities which could be responsible for 
downregulation of CRABP2 in GBM, including epigenetic causes such as miRNAs, 
DNA methylation and histone deacetylation. Sequence analysis of residue K102, in 
GBM tissue and cell lines, responsible for posttranslational modification, was also 
performed.  
 
My data showed that CRABP2 is not the target of miRNA-34a and miRNA-1262. 
There is no mutation in K102 of CRABP2 amino acid responsible for the interaction 
with Ubc9, SUMO ligase which triggers the SUMOylation. However, I could confirm 
that DNA methylation inhibitor 5-aza can increase CRABP2 expression and inhibits 
cell viability in GBM cell lines. Moreover, I investigated the anti-cancer mechanism of 
VPA alone and in combination with RA testing their influence on the CRABP2 protein, 
in vitro. Here I revealed at first that VPA increases expression of CRABP2 in 
cytoplasm of GBM cell lines contributing to the clinical properties of VPA in GBM. The 
combination of VPA with RA increases CRABP2 expression further. Inhibition of 
proliferation and increase in apoptosis in GBM cells are probably due to the two 
distinct mechanisms. In conclusion this data supports the statement that VPA as 
HDAC inhibitor has anti-cancer properties in GBM and further suggests that VPA in 
combination with RA can be a promising anti-cancer therapy for GBM and could 
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